Symposium Report: Developing Strategies to Block the Transmission of Leprosy

DEBORAH MENSAH-AWERE*, MARTIN W. BRATSCHI**,***, PETER STEINMANN**,***, JESSICA K. FAIRLEY**** & THOMAS P. GILLIS*
*effect:hope, Markham, Canada
**Swiss Tropical and Public Health Institute, Basel, Switzerland
***University of Basel, Basel, Switzerland
****Emory School of Medicine, Atlanta, GA, USA

Accepted for publication 24 May 2015

Context

Remarkable progress has been made in the treatment and management of leprosy over the last 60 years. Current control strategies rest on early detection of disease and appropriate multidrug therapy (MDT) to cure the patient and halt transmission within the community. These strategies are built on a solid understanding of therapeutics for mycobacterial diseases but suffer from an incomplete understanding of transmission of Mycobacterium leprae and a shortage of tools that can truly diagnose leprosy at an early stage. Accordingly, transmission continues in many areas of the world.

To clarify the current state of our knowledge of M. leprae transmission and to establish a research agenda to address gaps in our understanding of transmission, an international symposium entitled “Developing Strategies to Block the Transmission of Leprosy” was organized and sponsored by effect:hope (The Leprosy Mission Canada) and held on May 29–30, 2014. The meeting was hosted by the National School of Tropical Medicine, Baylor College of Medicine in Houston, Texas.

Goals and Objectives of Symposium

The goal of the symposium was to establish a research agenda, aimed at bridging the gaps in our understanding of M. leprae transmission, which will complement a global research strategy focused on eliminating leprosy.
The objectives were:

1. To identify the key gaps in our understanding of *M. leprae* transmission
2. To organise gaps into priority areas
3. To propose specific areas of investigation to address these priority areas

**SYMPOSIUM CONTENT**

**Keynote speakers**

*"The NTDs: Prospects for Elimination."* Peter Hotez, National School of Tropical Medicine, USA.

Peter Hotez presented an overview of the global burden of Neglected Tropical Diseases (NTDs) and their impact on health and on exacerbating the effects of poverty. Dr. Hotez discussed the current strategies in place for NTD control and elimination such as Mass Drug Administration and the impact it has had on reducing NTD prevalence. He highlighted the issues surrounding Disability-Adjusted Life Years (DALY) and how leprosy’s very low DALY may not accurately reflect its sustained effect on people affected by leprosy. Dr. Hotez suggested that the London Declaration may be overly simplistic when considering leprosy with regard to its road map and he supports focusing efforts on interrupting transmission for eventual elimination of leprosy.

*"Tracing Our Path to Today."* Paul Fine, London School of Hygiene and Tropical Medicine, UK.

Paul Fine described the history of leprosy as a disease including its disappearance from Northern Europe and the first attempts to estimate the global burden of the disease. Prof. Fine also shared current data on leprosy prevalence citing India, Brazil and Indonesia as the countries that account for 80% of new cases as of 2012. Prof. Fine discussed some of the possible theories related to *M. leprae* transmission and the reasons for the decline in leprosy prevalence globally. He also shared some of the issues related to semantics facing those working in the leprosy field and the impact this has on addressing *M. leprae* transmission.

*"Systematic literature review on current knowledge regarding the transmission of leprosy (Hansen’s disease)."* Martin Bratschi, Swiss Tropical and Public Health Institute, Switzerland.

Martin Bratschi presented the findings from the systematic review of the peer-reviewed literature pertaining to *M. leprae* transmission which was carried out to assess the current state of knowledge on this topic. Dr. Bratschi showed that the systematic literature review identified a total of 79 relevant articles providing solid evidence for *M. leprae* transmission among contacts and for zoonotic leprosy in the Southern States of the USA. He also reported that based on the extant evidence, skin-to-skin contact, aerosols/droplets and shedding of bacteria into the environment and subsequent infection, all remain possible options and there is no study which has unequivocally demonstrated the mechanisms by which *M. leprae* bacteria are transmitted. The full literature review entitled “Current knowledge on *Mycobacterium leprae* transmission: a systematic literature review” is published concurrently with this article.

Jan Hendrik Richardus stated that the primary purposes of current leprosy models are to predict the course of leprosy incidence and to analyse the impact of various intervention strategies. He gave an overview of the Lechat, SIMLEP and SIMCOLEP mathematical models used for leprosy. He also highlighted some of the results from current leprosy modeling efforts including the cost-effectiveness of single-dose rifampin chemoprophylaxis and the impact of early diagnosis and treatment.

ENDEMİC COUNTRIES PRESENTATIONS

Representatives from five countries discussed the current trends in M. leprae transmission and control in their respective countries.

- Brazil (Rosa Castillia Soares, Ministry of Health, Sao Paulo, Brazil)
- India (Sunil Anand, TLMI India, Delhi, India)
- Ethiopia (Abraham Aseffa, AHRI/ALERT, Addis Ababa, Ethiopia)
- Bangladesh (Shaikh Hossain, ICDDR,B, Bangladesh)
- Philippines (Marivic Balagon, LWM Center for TB & Leprosy Research, Cebu, Philippines)

The general themes were:

1. Leprosy control programmes have become decentralised and integrated into general health systems
2. Reduced numbers of cases were reported in the early 2000’s
3. A high proportion of MB cases remain in Ethiopia and the Philippines
4. All five countries noted stable transmission in children
5. The rate of grade 2 disabilities overall has shown no significant change
6. There is decreasing expertise in case finding
7. High endemic pockets remain in most countries and appear to be related to lack of access to care, and poverty

BREAKOUT SESSIONS

Breakout sessions were held to discuss the following key topics related to M. leprae transmission: reservoir, parasite and host. Each breakout session began with a panel of experts speaking on key topics related to the session. Discussion groups were then formed around specific sub-topics and a rapporteur for each group was selected. Dr. Edith Bahmanyar of the Novartis Foundation then facilitated plenary discussions around the key findings presented by each rapporteur. The goal of the sessions was to identify and define the gaps in knowledge and needs within the key topic areas that would lead to an improved understanding of M. leprae transmission and provide new tools and strategies to block M. leprae transmission.

RESERVOIR

Expert Panel: Active cases (Paul Saunderson), Occult human reservoir (Cairns Smith), Animal reservoir (Richard Truman) and Environmental reservoir (Ravindra Turankar)
Sub-topics: 1. Active cases/occult human reservoirs (Saunderson/Smith)
   2. Animal/Environmental reservoirs (Truman/Turankar)

**PARASITE**

Expert Panel: *M. leprae* genome (Pushpendra Singh); *M. lepromatosis* (Xiang-Yang Han)

Sub-topics: 1. Pathogen characteristics (Singh/Han)
   2. Genotyping (Singh/Han)

**HOST**

Expert Panel: Genetics (Erwin Schurr), Immunology (Tom Hawn), Vaccines (Steve Reed), Diagnostics (Annemiek Geluk), Portal of exit/entry of *M. leprae* (Eric Brenner)

Sub-topics: 1. Genetics, Immunology (Shurr, Hawn)
   2. Vaccines/Diagnostics (Reed, Geluk)
   3. Portals of exit-entry of *M. leprae* (Brenner)

**PARTNERS**

Partners from an array of government and nongovernment research and research funding organizations presented their current research priorities and funding commitments as well as successful projects related to leprosy research and control. The partners represented were: National Institute of Allergy and Infectious Disease (NIAID, USA), Pan-American Health Organization (PAHO), The Leprosy Research Initiative (LRI) and Novartis Foundation (Switzerland).

**GAPS IN OUR UNDERSTANDING OF *M. leprae* TRANSMISSION AND IDENTIFIED NEEDS**

Based on the breakout sessions and the literature review on *M. leprae* transmission (see Keynote Speakers and 2) the following gaps in our understanding of *M. leprae* transmission and needs to fill these gaps were identified.

1. **Human-to-human transmission of M. leprae**

   Studies have clearly shown that close proximity to leprosy patients increases the risk of contracting the disease. However, other members of endemic communities who are potentially asymptotically infected carriers may also contribute to the transmission of *M. leprae*.

   **Gap 1: Human Reservoirs**

   We do not understand the full extent of the human reservoir of *M. leprae*; specifically the roles of undiagnosed patients, patient contacts and other members of endemic communities in perpetuating *M. leprae* transmission are unknown.

   **Needs to fill gap 1:**
   a) Discovery of biomarkers for: all clinical cases of leprosy, subclinical infections and asymptomatic carriers.
   b) Develop platforms for field-friendly diagnostic tests.
2. Route of entry/exit of M. leprae in humans

A series of case reports appear to show that injection of M. leprae at the site of skin trauma (e.g. by tattoo or accident) can lead to localised as well as disseminated manifestations of leprosy. For most leprosy cases, there is however no clear sign that entry of the pathogen occurred through skin trauma, and the available evidence points more towards the involvement of the upper respiratory tract.

Gap 2: Entry and exit route
We do not understand the route of entry and exit of M. leprae in humans.

Needs to fill gap 2:
- a) Assess the role of colonization and route of entry (e.g. nasal-oral mucosa, skin and gastrointestinal tract) of M. leprae into the human host.
- b) Investigate potential roles of co-infections on the entry/exit of M. leprae from the human host (e.g. amoebiasis).
- c) Study the stages of pathogenicity of M. leprae to understand the migration (port of entry to the site of initial lesion to point of exit) of M. leprae inside the human host.

3. Role of animals, the environment or insects in the transmission of M. leprae

In the Southern USA, leprosy has been shown to exist as a zoonosis, based on M. leprae strain identification, indicating that there is transmission of M. leprae between armadillos and humans. However, in other parts of the world, the role of animals as reservoirs or vectors in M. leprae transmission remains unclear. It is also unknown how the recently described existence of M. leprae in the environment contributes to the spread of the disease.

Gap 3a: Roles of animals or vectors
We do not understand the role animals (armadillos outside of the southern USA and other animals) or vectors (e.g. insects or amoeba) play in the transmission of M. leprae.

Needs to fill gap 3a:
- a) Investigate how the distribution of M. leprae infection in armadillos is spreading in the Americas and how this affects the occurrence of human leprosy.
- b) Investigate the genetic diversity of M. leprae in armadillos to better understand zoonotic and cross-species transmission.
- c) Systematically investigate the possible role of animals (e.g. by serological surveillance) other than armadillos in M. leprae transmission in different endemic areas worldwide.
- d) Investigate the biological relationship between M. leprae and amoeba.
4. Role of Poverty in Transmission

It has been demonstrated that the socio-economic status of an individual appears to affect the risk of contracting leprosy. However, the driver of this correlation is not clear. Whilst there was not a breakout session dedicated to the topic of poverty and *M. leprae* transmission, it was a reoccurring theme discussed in several sessions of the symposium.

#### Gap 4: Role of poverty

We do not understand how poverty acts as a risk factor for *M. leprae* transmission.

**Needs to fill gap 4:**

a) Investigate the role of poverty-related factors, such as nutrition, hygiene and crowding on *M. leprae* transmission.

5. Role of Host-Parasite Interaction in Transmission

Despite recent advances in our understanding of *M. leprae* genetic diversity and the cellular immune response of leprosy patients, there are considerable gaps in our understanding of the interaction between *M. leprae* and the human host.

#### Gap 5: Host-pathogen interaction

We do not sufficiently understand the impact of the interaction between *M. leprae* and the human host on *M. leprae* transmission.

**Needs to fill gap 5:**

a) Investigate relationship between *M. leprae* genetic characteristics and virulence, growth kinetics, drug resistance, tropism for nerves and the tendency to cause reactions.

b) Understand the role of host genetic risk factors in susceptibility and resistance to *M. leprae* infection, clinical progression of leprosy and reactions.

c) Understand how the immune response affects the manifestation of the *M. leprae* infection (including establishing of infection, progression of disease, nasal carriage and reactions) and eventually transmission of *M. leprae*.

d) Increase understanding of similarities/differences between *M. leprae* and *M. lepromatosis*. 

---

**Gap 3b: Role of environmental sources**

We do not understand the source and relevance for transmission of *M. leprae* in the environment (e.g. in soil or water).

**Needs to fill gap 3b:**

a) Systematically investigate the presence of *M. leprae* in the environment in different endemic settings.

b) Use genotyping to characterize environmental *M. leprae* to determine how it relates to genotypes found in human infections in the same area.

c) Demonstrate viability and role in transmission of environmental *M. leprae*. 

---

**Blocking transmission of leprosy**
6. Transmission Networks

Recent evidence has shown that depending on the endemic setting, there are various types of *M. leprae* transmission networks.

**Gap 6: Transmission networks**

We do not understand the diversity and relevance of the various *M. leprae* transmission networks.

**Needs to fill gap 6:**

a) Increase collection of genome sequenced *M. leprae* strains with isolates from various origins (e.g. worldwide, PB patients) which are complemented with detailed epidemiological data.

b) Investigate genetic diversity of *M. leprae* from different sources (patients, nasal carriers, zoonotic and environmental) and various settings (e.g. high and low endemic) to study the transmission ecology at the community level.

c) Develop molecular epidemiology tools which are customised to a region to allow for fine typing from primary samples and investigation of transmission links.

7. Improving Epidemiology Data

Despite the elimination of leprosy in many countries, hot-spots of transmission with more than 1 case per 10,000 inhabitants and active transmission remain.

**Gap 7: Enhanced epidemiological data**

We do not fully understand the geographic distribution of leprosy, especially at a sub-national level.

**Needs to fill gap 7:**

a) Improve the quality of national epidemiological surveillance data including sub-national geographic variation and prevalence data based on local population densities.

b) Implement contact tracing and active case finding strategies to identify transmission hot-spots.

c) Digitalize leprosy surveillance to improve data access and timely identification of areas with high case numbers.

Conclusion and way forward

The *Developing Strategies to Block the Transmission of Leprosy* symposium brought together a broad spectrum of expertise in the field of infectious diseases (Table 1), in order to identify the key gaps that exist in our knowledge of *M. leprae* transmission as well as associated needs to close those gaps. Key overarching research principles that will help to improve our
understanding of *M. leprae* transmission were further identified from both the literature review on *M. leprae* transmission and during discussions at the symposium. These research principles are related to study design, the type of data to be collected in the course of studies and the capacity to conduct research in endemic areas. Specifically, it was concluded, that it is of great importance that long-term studies are performed and aspects of *M. leprae* transmission are monitored over several years. Only such longitudinal studies will have the potential to demonstrate how any novel tool, intervention or control measures can potentially affect the transmission of *M. leprae*. Furthermore, the degree of detail and types of data collected in different studies vary considerably and make comparison between findings from different studies difficult. The leprosy research and control communities should strive to define a minimal and standardised set of high quality clinical and demographic data that should be collected about participants in all studies. Researchers should further consider establishing a biobank of samples relevant for *M. leprae* transmission research. Finally, for the long-term research efforts required to eventually block the transmission of *M. leprae* it is of utmost importance to continue to support, expand and maintain research infrastructure and capacity in leprosy endemic areas. Likewise, government entities involved in leprosy control should continue to receive technical and other support so as to collect high quality epidemiological data about trends in the number of leprosy cases detected and how interventions are affecting the spread of the disease.

The key gaps and needs identified during this symposium and reported here are essential in shaping a global research agenda designed to block transmission of *M. leprae* and move toward eliminating the disease. These research priorities will form the foundation of the Transmission Research Initiative (TRI) which will be launched in October 2015 by effect:hope and partners, with a goal to support research aimed at closing gaps in our understanding of *M. leprae* transmission.

**Acknowledgements**

We would like to thank all participants for their time and effort in helping to make this symposium a success. We would also like to specifically extend our gratitude to National School of Tropical Medicine, Baylor College of Medicine for hosting the symposium. The symposium organizers Peter Hotez, Tom Gillis, Anna Wickenden, Kenneth Wong, Monica Cazares, and Cynthia Johnson wish to thank all plenary speakers and the symposium facilitator Edith Bahmanyar for their contributions. The symposium and participant costs were funded by effect:hope (The Leprosy Mission Canada).

**References**

### Table 1. List of Participants affiliations

<table>
<thead>
<tr>
<th>Participant</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erwin Schurr</td>
<td>McGill University, Montreal, Canada</td>
</tr>
<tr>
<td>Thomas Hawn</td>
<td>University of Washington, Seattle, WA, USA</td>
</tr>
<tr>
<td>Steve Reed</td>
<td>Infectious Disease Research Institute, Seattle, WA, USA</td>
</tr>
<tr>
<td>Annemieck Geluk</td>
<td>Leiden University Medical Center, Leiden, The Netherlands</td>
</tr>
<tr>
<td>Pushpendrah Singh</td>
<td>Ecole Polytechnique Federale de Laisanne (EPFL), Lausanne, Switzerland</td>
</tr>
<tr>
<td>Gerd Pluschke</td>
<td>Swiss Tropical and Public Health Institute, Basel, Switzerland</td>
</tr>
<tr>
<td>W. Cairns Smith</td>
<td>University of Aberdeen, Aberdeen, Scotland</td>
</tr>
<tr>
<td>Paul Fine</td>
<td>London School of Hygiene and Tropical Medicine, London, UK</td>
</tr>
<tr>
<td>Peter Hotez</td>
<td>National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA</td>
</tr>
<tr>
<td>Jan Hendrik Richardus</td>
<td>Erasmus MC, University Medical Center, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>Eric Brenner</td>
<td>University of South Carolina, Columbia, SC, USA</td>
</tr>
<tr>
<td>Masanori Matsuoka</td>
<td>Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan</td>
</tr>
<tr>
<td>Ravindra Turanka</td>
<td>The Leprosy Mission India and Stanley Browne Laboratory, Delhi, India</td>
</tr>
<tr>
<td>Marivic Balagon</td>
<td>Leonard Wood Memorial Center for TB and Leprosy Research, Cebu, The Philippines</td>
</tr>
<tr>
<td>Edith Bahmanyar</td>
<td>Novartis Foundation, Basel, Switzerland</td>
</tr>
<tr>
<td>Rosa Castalia Soares</td>
<td>Leprosy Program, Ministry of Health, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>Sunil Anand</td>
<td>The Leprosy Mission Trust India, Delhi, India</td>
</tr>
<tr>
<td>Ruth Butlin</td>
<td>Nilphamari, Bangladesh</td>
</tr>
<tr>
<td>Abraham Aseffa</td>
<td>Armauer Hansen Research Institute and ALERT, Addis Ababa, Ethiopia</td>
</tr>
<tr>
<td>Shaikh Shahed Hossain</td>
<td>International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh</td>
</tr>
<tr>
<td>Jessica Fairley</td>
<td>Emory School of Medicine, Atlanta, GA, USA</td>
</tr>
<tr>
<td>Martin Bratschi</td>
<td>Swiss Tropical and Public Health Institute, Basel, Switzerland</td>
</tr>
<tr>
<td>Anna Wickenden</td>
<td>effect:hope (The Leprosy Mission Canada), Markham, Canada</td>
</tr>
<tr>
<td>Peter Derrick</td>
<td>effect:hope (The Leprosy Mission Canada), Markham, Canada</td>
</tr>
<tr>
<td>Tom Gillis</td>
<td>effect:hope (The Leprosy Mission Canada), Markham, Canada</td>
</tr>
<tr>
<td>Kenneth Wong</td>
<td>effect:hope (The Leprosy Mission Canada), Markham, Canada</td>
</tr>
<tr>
<td>Paul Sauderson</td>
<td>American Leprosy Mission, Greenville, SC, USA</td>
</tr>
<tr>
<td>Christa Kasang</td>
<td>German Leprosy and TB Relief Association, Wurzburg, Germany</td>
</tr>
<tr>
<td>Wim van Brakel</td>
<td>Netherlands Leprosy Relief, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Tamara Prinsenberg</td>
<td>Netherlands Leprosy Relief, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Ken Gibson</td>
<td>The Leprosy Mission Ireland, Dublin, Ireland</td>
</tr>
<tr>
<td>Xiang-Yang Han</td>
<td>MD Anderson, Houston, TX, USA</td>
</tr>
<tr>
<td>Bide Landry</td>
<td>WHO-AFRO, Brazzaville, Republic of Congo</td>
</tr>
<tr>
<td>David Scollard</td>
<td>National Hansen’s Disease Programs, Baton Rouge, LA, USA</td>
</tr>
<tr>
<td>Rahul Sharma</td>
<td>National Hansen’s Disease Programs, Baton Rouge, LA, USA</td>
</tr>
<tr>
<td>Richard Truman</td>
<td>National Hansen’s Disease Programs, Baton Rouge, LA, USA</td>
</tr>
<tr>
<td>Christine Sizemore</td>
<td>NIAID, National Institutes of Health, Bethesda, MD, USA</td>
</tr>
<tr>
<td>Terry Williams</td>
<td>Houston Department of Health and Human Services, Houston TX, USA</td>
</tr>
<tr>
<td>Steven Mays</td>
<td>Houston Department of Health and Human Services, Houston TX, USA</td>
</tr>
</tbody>
</table>